Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Given the clinical potential of poly(ADP-ribose) polymerases (PARP) imaging for the detection and stratification of various cancers, the development of novel PARP imaging probes with improved pharmacological profiles over established PARP imaging agents is warranted. Here, we present a novel F-labeled PARP radiotracer based on the clinically superior PARP inhibitor talazoparib. An automated radiosynthesis of [F]talazoparib (RCY: 13 ± 3.4%; = 4) was achieved using a "design of experiments" (DoE) optimized copper-mediated radiofluorination reaction. The chiral product was isolated from the reaction mixture using 2D reversed-phase/chiral radio-HPLC (>99% ee). (8,9)-[F]Talazoparib demonstrated PARP binding in HCC1937 cells and showed an excellent tumor-to-blood ratio in xenograft-bearing mice (10.2 ± 1.5). Additionally, a favorable pharmacological profile in terms of excretion, metabolism, and target engagement was observed. This synthesis of [F]talazoparib exemplifies how DoE can enable the radiosyntheses of synthetically challenging radiolabeled compounds of high interest to the imaging community.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.jmedchem.1c00903 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acetylated monosaccharide functionalized co-ligand based strong anticancer Pt(II) complexes: Synthesis characterization and biological analyses.
J Inorg Biochem
August 2025
Inner Mongolia University, Research Center for Glycochemistry of Characteristic Medicinal Resources, Department of Chemistry and Chemical Engineering, Hohhot, People's Republic of China. Electronic address:
In this study, we modified ONS-donor tridentate salicylaldimine main ligand-based Pt(II) complexes with monosaccharide functionalized pyridine co-ligand. All these complexes (C1-C12) were prepared in two steps continuous reaction by firstly, abstracting the ancillary chloride of the starting complexes with AgBF and secondly, adding the acetylated β-d-glucose conjugated pyridine. All these complexes were analyzed for their in vitro anticancer potency in human's gastric cancer MKN 45, colon cancer RPMI 4788 and non-small cell lung cancer A549 cells.
View Article and Find Full Text PDFMolecular Targets for Pharmacotherapy of Head and Neck Squamous Cell Carcinomas.
Curr Issues Mol Biol
August 2025
Silesia LabMed, Centre for Research and Implementation, Medical University of Silesia in Katowice, 40-752 Katowice, Poland.
Head and neck squamous cell carcinomas (HNSCCs) represent a heterogeneous group of tumors with a complex molecular profile. Despite therapeutic advances, patient prognosis remains poor, emphasizing the need for more effective treatment strategies. Traditional chemotherapy, with cisplatin and 5-fluorouracil (5-FU), remains the gold standard but is limited by toxicity and tumor resistance.
View Article and Find Full Text PDFPreparation of Novel PARP1 Inhibitors and Their Use in Cancer Treatment.
ACS Med Chem Lett
August 2025
Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States.
Poly-(ADP-ribose) polymerase 1 (PARP1) is the most widely studied PARP enzyme, which plays a significant role in DNA damage repair. PARP1 inhibition has emerged as a clinically validated strategy to selectively target two cancer subtypes: tumors with homologous recombination deficiency (HRD) and Epstein-Barr virus (EBV)-associated malignancies. This patent highlights the synthesis and pharmaceutical compositions of PARP1 inhibitors and their uses in the treatment of cancer.
View Article and Find Full Text PDFNovel Isoindolinone-Containing PARP Inhibitors: Synthesis and Therapeutic Applications in CNS Cancer Treatment.
ACS Med Chem Lett
August 2025
Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States.
This patent discloses the development and therapeutic applications of novel poly-(ADP-ribose) polymerase (PARP) inhibitors featuring an isoindolinone scaffold. These isoindolinone-based PARP inhibitors represent a strategically designed class of central nerve system (CNS) cancer therapeutics that combine potent PARP inhibitory activity with enhanced blood-brain barrier (BBB) permeability.
View Article and Find Full Text PDFBCL-xL dependency in chromophobe renal cell carcinoma.
Cancer Gene Ther
August 2025
Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Chromophobe renal cell carcinoma (ChRCC) is the third most common subtype of kidney cancer, with limited therapeutic options. Using BH3 profiling to screen ChRCC-derived cell lines, we discovered that BH3 peptides targeting BCL-xL promote apoptosis in ChRCC. Downregulation of BCL2L1 is sufficient to induce apoptosis in ChRCC-derived cells, consistent with our screening results.
View Article and Find Full Text PDF